Autonomix Medical, Inc. (AMIX) Stock Score, Valuation & Financial Research

Autonomix Medical, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AMIX

Autonomix Medical, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.83. These figures are a research snapshot, not a buy or sell recommendation.

What Autonomix Medical, Inc. does

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Autonomix Medical is a development-stage medical device company that has not yet generated any product sales revenue. The company is currently focused on the research, development, and clinical testing of its proprietary catheter-based sensing and ablation technology platform, and it relies on capital raises to fund its operations.

Products and services

  • The company is developing a catheter-based system that incorporates a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system for the treatment of nervous system disorders.

Customer types

Hospitals and Ambulatory Surgical Centers; Interventional Pain Specialists.

Suppliers, materials and equipment

  • Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its medical device components and prototypes. Source

Business strengths to evaluate

  • Proprietary microchip-enabled sensing architecture Source

Business risks and research considerations

  • Development-stage status with no product revenue Source
  • Going-concern uncertainty Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AMIX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.83
Market capitalization:
2.08M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -16.11M
Free cash flow:
USD -12.29M
Cash:
USD 3.46M
Total debt:
USD 0.00
EPS:
USD -46.49

What stands out

  • Free cash flow is USD -12.29M, negative for the stored period.
  • The balance sheet shows USD 3.46M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.46M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AMIX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AMIX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AMIX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AMIX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of AMIX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research AMIX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.